These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37081729)

  • 1. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
    Sonoda T; Umeda Y; Demura Y; Tada T; Nakashima K; Anzai M; Yamaguchi M; Shimada A; Ohi M; Honjo C; Waseda Y; Akai M; Ishizuka T
    Cancer Med; 2023 Jun; 12(12):13041-13053. PubMed ID: 37081729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
    Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
    Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
    Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
    Anzai M; Morikawa M; Okuno T; Umeda Y; Demura Y; Sonoda T; Yamaguchi M; Kanno K; Shiozaki K; Ameshima S; Akai M; Ishizuka T
    Medicine (Baltimore); 2017 Dec; 96(51):e9320. PubMed ID: 29390506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.
    Xin D; Song Y; Mu L; Zhang B; Qi L; Gao J; Wang X; Xu J; Qu T; Huang J
    Thorac Cancer; 2023 May; 14(15):1392-1397. PubMed ID: 37035870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
    Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K
    Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
    Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
    Li R; Liang H; Li J; Shao Z; Yang D; Bao J; Wang K; Xi W; Gao Z; Guo R; Mu X
    BMC Cancer; 2024 Jan; 24(1):107. PubMed ID: 38238648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 16. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.
    Nakashima K; Umeda Y; Demura Y; Sonoda T; Tada T; Yamaguchi M; Anzai M; Kadowaki M; Oi M; Honjo C; Mitsui M; Waseda Y; Ishizuka T
    Oncology; 2024; 102(7):593-603. PubMed ID: 38290482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
    Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
    Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
    Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
    Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
    Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.